Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract

Yi Wen Wang; Wei Ming Li; Wen Jeng Wu; Chee Yin Chai; Tsuey Yu Chang; Yin Sun; Chih Jen Cheng; Yow Ling Shiue; Shu Jem Su; Hong Lin Cheng; Hsiao Sheng Liu; Nan Haw Chow

doi:10.1016/j.ajpath.2013.05.015

Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract

Yi Wen Wang, Wei Ming Li, Wen Jeng Wu, Chee Yin Chai, Tsuey Yu Chang, Yin Sun, Chih Jen Cheng, Yow Ling Shiue, Shu Jem Su, Hong Lin Cheng, Hsiao Sheng Liu, Nan Haw Chow

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Upper urinary tract urothelial carcinoma is a relatively uncommon disease and is diagnosed more frequently at advanced stages. The prognosis of these patients mainly has been related to tumor stage and grade. As a result, the definition of prognostic indicators enabling precise patient selection is mandatory for neoadjuvant or adjuvant therapies. The epithelial membrane protein (EMP2) was identified as one of the up-regulated genes by isoflavones. EMP2 overexpression suppressed foci formation, anchorage-independent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05). In addition, a cross-talk between EMP2 and integrins αV and β3 was shown in the regulation of cell adhesion and migration. Higher EMP2 expression was associated with a better progression-free survival (P = 0.008) and cancer-related death (P < 0.001). EMP2 was identified as a tumor-suppressor gene in urinary tract urothelial carcinoma and may be an innovative co-targeting candidate for designing integrin-based cancer therapy.

Original language	English
Pages (from-to)	709-719
Number of pages	11
Journal	American Journal of Pathology
Volume	183
Issue number	3
DOIs	https://doi.org/10.1016/j.ajpath.2013.05.015
Publication status	Published - 2013 Sept

All Science Journal Classification (ASJC) codes

Pathology and Forensic Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ajpath.2013.05.015

Cite this

Wang, Y. W., Li, W. M., Wu, W. J., Chai, C. Y., Chang, T. Y., Sun, Y., Cheng, C. J., Shiue, Y. L., Su, S. J., Cheng, H. L., Liu, H. S., & Chow, N. H. (2013). Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract. American Journal of Pathology, 183(3), 709-719. https://doi.org/10.1016/j.ajpath.2013.05.015

@article{b849ca3b3c1e4a0ba194093b5d88459e,

title = "Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract",

abstract = "Upper urinary tract urothelial carcinoma is a relatively uncommon disease and is diagnosed more frequently at advanced stages. The prognosis of these patients mainly has been related to tumor stage and grade. As a result, the definition of prognostic indicators enabling precise patient selection is mandatory for neoadjuvant or adjuvant therapies. The epithelial membrane protein (EMP2) was identified as one of the up-regulated genes by isoflavones. EMP2 overexpression suppressed foci formation, anchorage-independent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05). In addition, a cross-talk between EMP2 and integrins αV and β3 was shown in the regulation of cell adhesion and migration. Higher EMP2 expression was associated with a better progression-free survival (P = 0.008) and cancer-related death (P < 0.001). EMP2 was identified as a tumor-suppressor gene in urinary tract urothelial carcinoma and may be an innovative co-targeting candidate for designing integrin-based cancer therapy.",

author = "Wang, {Yi Wen} and Li, {Wei Ming} and Wu, {Wen Jeng} and Chai, {Chee Yin} and Chang, {Tsuey Yu} and Yin Sun and Cheng, {Chih Jen} and Shiue, {Yow Ling} and Su, {Shu Jem} and Cheng, {Hong Lin} and Liu, {Hsiao Sheng} and Chow, {Nan Haw}",

note = "Funding Information: Supported by grants NSC 92-2320-B-006-071, NSC 93-2320-B-006-025, NSC 94-2320-B-006-007 , and NSC 98-2320-B-006-022-MY3 from the National Science Council , Taiwan; and EX99-9930BI from the National Health Research Institutes , Taiwan. ",

year = "2013",

month = sep,

doi = "10.1016/j.ajpath.2013.05.015",

language = "English",

volume = "183",

pages = "709--719",

journal = "American Journal of Pathology",

issn = "0002-9440",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract

AU - Wang, Yi Wen

AU - Li, Wei Ming

AU - Wu, Wen Jeng

AU - Chai, Chee Yin

AU - Chang, Tsuey Yu

AU - Sun, Yin

AU - Cheng, Chih Jen

AU - Shiue, Yow Ling

AU - Su, Shu Jem

AU - Cheng, Hong Lin

AU - Liu, Hsiao Sheng

AU - Chow, Nan Haw

N1 - Funding Information: Supported by grants NSC 92-2320-B-006-071, NSC 93-2320-B-006-025, NSC 94-2320-B-006-007 , and NSC 98-2320-B-006-022-MY3 from the National Science Council , Taiwan; and EX99-9930BI from the National Health Research Institutes , Taiwan.

PY - 2013/9

Y1 - 2013/9

N2 - Upper urinary tract urothelial carcinoma is a relatively uncommon disease and is diagnosed more frequently at advanced stages. The prognosis of these patients mainly has been related to tumor stage and grade. As a result, the definition of prognostic indicators enabling precise patient selection is mandatory for neoadjuvant or adjuvant therapies. The epithelial membrane protein (EMP2) was identified as one of the up-regulated genes by isoflavones. EMP2 overexpression suppressed foci formation, anchorage-independent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05). In addition, a cross-talk between EMP2 and integrins αV and β3 was shown in the regulation of cell adhesion and migration. Higher EMP2 expression was associated with a better progression-free survival (P = 0.008) and cancer-related death (P < 0.001). EMP2 was identified as a tumor-suppressor gene in urinary tract urothelial carcinoma and may be an innovative co-targeting candidate for designing integrin-based cancer therapy.

AB - Upper urinary tract urothelial carcinoma is a relatively uncommon disease and is diagnosed more frequently at advanced stages. The prognosis of these patients mainly has been related to tumor stage and grade. As a result, the definition of prognostic indicators enabling precise patient selection is mandatory for neoadjuvant or adjuvant therapies. The epithelial membrane protein (EMP2) was identified as one of the up-regulated genes by isoflavones. EMP2 overexpression suppressed foci formation, anchorage-independent growth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05). In addition, a cross-talk between EMP2 and integrins αV and β3 was shown in the regulation of cell adhesion and migration. Higher EMP2 expression was associated with a better progression-free survival (P = 0.008) and cancer-related death (P < 0.001). EMP2 was identified as a tumor-suppressor gene in urinary tract urothelial carcinoma and may be an innovative co-targeting candidate for designing integrin-based cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84883178589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883178589&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2013.05.015

DO - 10.1016/j.ajpath.2013.05.015

M3 - Article

C2 - 23838430

AN - SCOPUS:84883178589

SN - 0002-9440

VL - 183

SP - 709

EP - 719

JO - American Journal of Pathology

JF - American Journal of Pathology

IS - 3

ER -

Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this